Literature DB >> 28571633

Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014.

Robert S Rosenson1, Michael E Farkouh2, Matthew Mefford3, Vera Bittner4, Todd M Brown4, Ben Taylor5, Keri L Monda5, Hong Zhao3, Yuling Dai3, Paul Muntner3.   

Abstract

BACKGROUND: Data prior to 2011 suggest that a low percentage of patients hospitalized for acute coronary syndromes filled high-intensity statin prescriptions upon discharge. Black-box warnings, generic availability of atorvastatin, and updated guidelines may have resulted in a change in high-intensity statin use.
OBJECTIVES: The aim of this study was to examine trends and predictors of high-intensity statin use following hospital discharge for myocardial infarction (MI) between 2011 and 2014.
METHODS: Secular trends in high-intensity statin use following hospital discharge for MI were analyzed among patients 19 to 64 years of age with commercial health insurance in the MarketScan database (n = 42,893) and 66 to 75 years of age with U.S. government health insurance through Medicare (n = 75,096). Patients filling statin prescriptions within 30 days of discharge were included. High-intensity statins included atorvastatin 40 or 80 mg and rosuvastatin 20 or 40 mg.
RESULTS: The percentage of beneficiaries whose first statin prescriptions filled following hospital discharge for MI were for high-intensity doses increased from 33.5% in January through March 2011 to 71.7% in October through November 2014 in MarketScan and from 24.8% to 57.5% in Medicare. Increases in high-intensity statin use following hospital discharge occurred over this period among patients initiating treatment (30.6% to 72.0% in MarketScan and 21.1% to 58.8% in Medicare) and those taking low- or moderate-intensity statins prior to hospitalization (from 27.8% to 62.3% in MarketScan and from 12.6% to 45.1% in Medicare). In 2014, factors associated with filling high-intensity statin prescriptions included male sex, filling beta-blocker and antiplatelet agent prescriptions, and attending cardiac rehabilitation within 30 days following discharge.
CONCLUSIONS: The use of high-intensity statins following hospitalization for MI increased progressively from 2011 through 2014.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery disease; drug use; hydroxymethylglutaryl-CoA reductase inhibitors; secondary prevention

Mesh:

Substances:

Year:  2017        PMID: 28571633     DOI: 10.1016/j.jacc.2017.03.585

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

1.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

2.  Gender disparity in the prescription of secondary prevention medications in a Malaysian primary care clinic.

Authors:  Noorhida Baharudin; Ahmad Muslim Ahmad Roslan; Mohamed Syarif Mohamed Yassin; Anis Safura Ramli; Aiza Nur Izdihar Zainal Abidin; Nurul Hidayatullaila Sahar; Nor Shazatul Salwana Din; Izyana Syazlin Ibrahim; Siti Nur Hidayah Abd Rahim; Nur Athirah Rosli
Journal:  Malays Fam Physician       Date:  2021-06-08

Review 3.  Irisin is an Effector Molecule in Exercise Rehabilitation Following Myocardial Infarction (Review).

Authors:  Shuguang Qin; Zhenjun Tian; Maxime Boidin; Benjamin J R Buckley; Dick H J Thijssen; Gregory Y H Lip
Journal:  Front Physiol       Date:  2022-06-29       Impact factor: 4.755

4.  Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines.

Authors:  H Robert Superko; Paul T Williams; Michael Dansinger; Ernst Schaefer
Journal:  Clin Cardiol       Date:  2018-11-30       Impact factor: 2.882

5.  Nonadherence in the Learning Healthcare System: Avoiding a Mountain by Seeing the Bumps.

Authors:  Andrew E Levy; P Michael Ho
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-10

6.  National Trends in Statin Use among the United States Nursing Home Population (2011-2016).

Authors:  Deborah S Mack; Anne L Hume; Jennifer Tjia; Kate L Lapane
Journal:  Drugs Aging       Date:  2021-03-11       Impact factor: 3.923

7.  Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol.

Authors:  Teresa N Harrison; Ronald D Scott; T Craig Cheetham; Shen-Chih Chang; Jin-Wen Y Hsu; Rong Wei; Deborah S Ling Grant; Susan H Boklage; Victoria Romo-LeTourneau; Kristi Reynolds
Journal:  Cardiovasc Drugs Ther       Date:  2018-08       Impact factor: 3.727

8.  Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries.

Authors:  Vera Bittner; Lisandro D Colantonio; Yuling Dai; Mark Woodward; Matthew T Mefford; Robert S Rosenson; Paul Muntner; Keri L Monda; Meredith L Kilgore; Byron C Jaeger; Emily B Levitan
Journal:  JAMA Cardiol       Date:  2019-09-01       Impact factor: 14.676

9.  Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.

Authors:  Hayato Akimoto; Akio Negishi; Shinji Oshima; Mitsuyoshi Okita; Sachihiko Numajiri; Naoko Inoue; Shigeru Ohshima; Daisuke Kobayashi
Journal:  Pharmacol Res Perspect       Date:  2018-11-07

10.  Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.

Authors:  Christopher P Cannon; James A de Lemos; Robert S Rosenson; Christie M Ballantyne; Yuyin Liu; Qi Gao; Tamara Palagashvilli; Shushama Alam; Katherine E Mues; Deepak L Bhatt; Mikhail N Kosiborod
Journal:  JAMA Cardiol       Date:  2021-06-16       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.